Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441297 | 0.92 | MMP13 (0.54) | ATRSMN1; SMN2MMP13MAPK1CYP3A4 | |
| SCHEMBL441294 | 0.85 | ATR (0.51) | ATRCYP3A4 | |
| SCHEMBL441224 | 0.82 | ATR (0.48) | ATRSMN1; SMN2MMP13CYP3A4KMT2A | |
| SCHEMBL12725888 | 0.76 | CYP1A2 (0.70) | SMN1; SMN2CYP3A4KMT2AGAA | |
| SCHEMBL14082493 | 0.74 | MMP13 (0.79) | SMN1; SMN2MMP13MAPK1CYP3A4HTT | |
| SCHEMBL439511 | 0.74 | ACVR1 (0.52) | ATR | |
| SCHEMBL26856722 | 0.73 | MAPK1 (0.65) | SMN1; SMN2MMP13MAPK1CYP3A4KMT2A | |
| SCHEMBL439516 | 0.71 | ATR (0.53) | ATRCYP3A4KMT2A | |
| SCHEMBL22573312 | 0.71 | MMP13 (0.49) | ATRSMN1; SMN2MMP13MAPK1KMT2A | |
| SCHEMBL19028142 | 0.71 | TSHR (0.76) | SMN1; SMN2MMP13MAPK1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | ATR 3803/4885SMN1; SMN2 3038/4885MMP13 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.